Skip to main content
. Author manuscript; available in PMC: 2009 Dec 9.
Published in final edited form as: Vaccine. 2008 Oct 14;26(52):6901–6907. doi: 10.1016/j.vaccine.2008.09.063

Figure 2. Determination of fully protective and sub-optimal doses of mAb specific for F1 or LcrV.

Figure 2

Wild-type C57BL/6 mice were infected intranasally with Y. pestis (10 LD-50; 2×105 CFU). The following day, mice were treated with the indicated doses of F1-specific mAb (top panel) or LcrV-specific mAb (bottom panel). Results depict percent survival over time post infection. Except for the lowest dose shown in each panel, which was only tested once, all data are pooled from 3 or more experiments using 5 mice/dose/experiment.